Abstract
Patients we consider as candidates to undergo electrophysiologic testing to define drug therapy are those who have supraventricular tachycardia (SVT) that is drug-resistant, that produces severe symptoms and those patients who have Wolff-Parkinson-White syndrome and a very rapid ventricular response during atrial fibrillation. Regarding patients who have ventricular tachycardia, we would evaluate those patients who are symptomatic during the ventricular tachycardia, and whose ventricular tachycardia is drug-resistant, occurs infrequently, and is more likely to be inducible electrophysiologically, such as those patients who have sustained ventricular tachycardia on the basis of coronary artery disease. Patients who are resuscitated from ventricular fibrillation should also be considered as candidates for an electrophysiologic study.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Martinus Nijhojf Publishers bv, The Hague.
About this chapter
Cite this chapter
Zipes, D.P. (1981). Role of Electrophysiology Testing to Define Drug Efficacy. In: Morganroth, J., Moore, E.N., Dreifus, L.S., Michelson, E.L. (eds) The Evaluation of New Antiarrhythmic Drugs. Developments in Cardiovascular Medicine, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-8270-3_16
Download citation
DOI: https://doi.org/10.1007/978-94-009-8270-3_16
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-8272-7
Online ISBN: 978-94-009-8270-3
eBook Packages: Springer Book Archive